A recent retrospective cohort study evaluated the duration of antipsychotic (AP) treatment among nursing home residents with dementia, revealing critical insights into the effectiveness of federal policies aimed at reducing AP use. The study analyzed 43,668 new episodes of AP initiation among 38,275 residents, focusing on treatment duration and discontinuation rates within six months of starting medication. Notably, the research assessed the impact of two significant federal initiatives: the National Partnership to Improve Dementia Care (2012) and the Five Star Rating system (2015).

The findings indicate that while there was a slight decline in the average duration of treatment—from 125.9 days pre-Partnership to 120.5 days post-Partnership—the overall impact of these policies on treatment duration was minimal. More concerning is the observation that over 50% of residents continued AP treatment beyond six months, despite the intended goals of these initiatives. The analysis demonstrated that residents who initiated APs after the Partnership (adjusted hazard ratio [aHR] = 1.17) and post-Five Star Rating (aHR = 1.19) were significantly more likely to discontinue treatment within six months compared to those who started during the pre-Partnership period.

These results underscore the need for a reevaluation of current strategies aimed at managing AP use in nursing homes. The modest reductions in treatment duration suggest that while policies may influence initial prescribing behaviors, they do not sufficiently address long-term treatment patterns. This highlights a potential gap in clinical practice and policy effectiveness, signaling an urgent call for innovative approaches to ensure that AP prescriptions are not only curtailed but also appropriately managed for the long-term health of dementia patients in nursing homes.

Source: academic.oup.com